Compugen Ltd.

CGEN Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%
Market cap
$187.6M
P/E
5.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
7/9
Altman Z
−0.37
Beneish M
−1.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 — — —

+8 more TTM periods

ROE
47.85% 0.00% 42.00% 0.00%
ROA
23.86% 26.68% 26.03% (24.95%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
32.75% 30.08% 28.02% (39.79%)
Average Days of Receivables
20.27 11.75 11.95 149.74
Free Cash Flow per Share
0.42 0.00 1.09 0.00
Free Cash Flow
40.04 — 101.69 —
Capital Expenditures
(0.69) — (0.69) —
Other line items
Cash ROIC
18.71% 0.00% 40.94% 0.00%
Accounts Receivable Turnover
22.80 26.49 28.40 2.79
Accounts Payable Turnover
4.86 3.54 3.16 0.00
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
81.06 106.28 92.84 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
33.23% 32.92% 31.28% 335.00%
Selling, General and Administrative Expense of Revenue
12.72% 12.88% 12.96% 138.90%
Share Based Compensation of Revenue
8.73% 0.00% 10.34% 0.00%
Operating CF/Net income
1.16 0.00 2.90 0.00
Depreciation/Fixed assets
(1.05) 0.00 (0.92) 0.00
Capex/Depreciation
0.95 — 1.10 —
Revenue per Share
0.78 0.77 0.78 0.07
Operating CF per Share
0.43 0.00 1.10 0.00
Capex per Share
(0.01) 0.00 (0.01) 0.00
Capex to Sales
0.01 0.00 0.01 0.00

Fold the line items

Columns are period end dates